Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

Andi77 Feb. 23 at 8:22 AM

$AKBA

0 · Reply

dow_is_at_50000_dollars Feb. 23 at 5:44 AM

$AKBA hate to see you guys going through this.

1 · Reply

StockHawkZero Feb. 23 at 5:30 AM

$AKBA Guys, revenues are unlikely to be over $40 mln in Q4. It is Q1 and especially Q2 we have to focus on.

0 · Reply

Mr_Pithy Feb. 23 at 1:14 AM

$AKBA “October 28, 2025 - “We believe our decision not to pursue a broad NDD-CKD label … is in the best interests of shareholders.” Specifically, Akebia abandoned the NDD application because FDA’s proposal would “require meaningfully more time and cost to complete.” November 17, 2025 - Institutional ownership was 53.83% (Fintel). February 22, 2026 - Institutional ownership is 51.00%. (Fintel). No one is surprised about a 2.83% drop, given the foregoing, correct? A reasonable argument can certainly be made that the modest percentage change is evidence that Institutions agreed with Akebia’s decision to act in the best interests of shareholders. Good luck 🍀 to all of us.

4 · Reply

PharmaExpert Feb. 23 at 1:12 AM

$AKBA is it thursday yet! 🔥 https://www.marketbeat.com/instant-alerts/akebia-therapeutics-akba-to-release-quarterly-earnings-on-thursday-2026-02-20/

0 · Reply

kyohann Feb. 23 at 12:58 AM

$AKBA Q4 2025 rev$49 mil IMO.

0 · Reply

Noname2022 Feb. 22 at 9:05 PM

$AKBA $DVA Anything less than 20% of Davita prescribers writing for the 20% of ESA hypo responders with 1st 30 days is a failure imho… widely available at Davita since Nov. 2025; wheres the Q4 LDO revenue?! https://ir.akebia.com/static-files/609bf97a-353c-47cd-aa61-693c9d06d337

1 · Reply

747rasta Feb. 22 at 9:01 PM

$AKBA

0 · Reply

ROCKET123 Feb. 22 at 8:39 PM

$AKBA It’s time to awaken the GIANT within…hmmm💎

0 · Reply

Noname2022 Feb. 22 at 8:35 PM

$AKBA https://assets.cureus.com/uploads/review_article/pdf/449323/20260108-69650-ifowjq.pdf

1 · Reply

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Feb 13, 2026, 4:57 PM EST - 9 days ago

Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 4, 2026, 8:00 AM EST - 18 days ago

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 2, 2026, 4:05 PM EST - 20 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2026, 1:21 PM EST - 5 weeks ago

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts

Jan 12, 2026, 8:00 AM EST - 5 weeks ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Jan 6, 2026, 8:00 AM EST - 6 weeks ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Dec 1, 2025, 7:00 AM EST - 2 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 2 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Nov 24, 2025, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 11:01 AM EST - 3 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 3 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 6:30 PM EST - 3 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 4, 2025, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

Oct 29, 2025, 2:13 PM EDT - 4 months ago

FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug

Oct 28, 2025, 4:30 PM EDT - 4 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 4 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Sep 5, 2025, 1:34 AM EDT - 6 months ago

Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 4:05 PM EDT - 6 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2025, 8:17 AM EDT - 6 months ago

Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection

Aug 21, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 7, 2025, 7:34 PM EDT - 7 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 7 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:00 AM EDT - 7 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 7 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 8, 2025, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 4, 2025, 8:00 AM EDT - 9 months ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 13, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 12:44 PM EDT - 10 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 10 months ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 20, 2025, 8:18 AM EDT - 1 year ago

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

MCHP

Mar 19, 2025, 10:17 PM EDT - 1 year ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 10:21 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Feb 10, 2025, 5:43 AM EST - 1 year ago

Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline

Jan 13, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 1 year ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 1 year ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 1 year ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Andi77 Feb. 23 at 8:22 AM

$AKBA

0 · Reply

dow_is_at_50000_dollars Feb. 23 at 5:44 AM

$AKBA hate to see you guys going through this.

1 · Reply

StockHawkZero Feb. 23 at 5:30 AM

$AKBA Guys, revenues are unlikely to be over $40 mln in Q4. It is Q1 and especially Q2 we have to focus on.

0 · Reply

Mr_Pithy Feb. 23 at 1:14 AM

4 · Reply

PharmaExpert Feb. 23 at 1:12 AM

$AKBA is it thursday yet! 🔥 https://www.marketbeat.com/instant-alerts/akebia-therapeutics-akba-to-release-quarterly-earnings-on-thursday-2026-02-20/

0 · Reply

kyohann Feb. 23 at 12:58 AM

$AKBA Q4 2025 rev$49 mil IMO.

0 · Reply

Noname2022 Feb. 22 at 9:05 PM

1 · Reply

747rasta Feb. 22 at 9:01 PM

$AKBA

0 · Reply

ROCKET123 Feb. 22 at 8:39 PM

$AKBA It’s time to awaken the GIANT within…hmmm💎

0 · Reply

Noname2022 Feb. 22 at 8:35 PM

$AKBA https://assets.cureus.com/uploads/review_article/pdf/449323/20260108-69650-ifowjq.pdf

1 · Reply

Noname2022 Feb. 22 at 8:32 PM

$AKBA

0 · Reply

Noname2022 Feb. 22 at 8:31 PM

$AKBA

0 · Reply

37iqtrader Feb. 22 at 8:28 PM

$AKBA smart money!

3 · Reply

MB76 Feb. 22 at 7:05 PM

$AKBA Why the new accounts other than FUD before Thursday!

0 · Reply

168_swingit Feb. 22 at 7:02 PM

$AKBA This is effed if they cannot successfuly commercialize vafseo. They only have less than a year to do this.

3 · Reply

Tumblingtom Feb. 22 at 5:58 PM

$AKBA What would revenue vafseo in Europe be for 2025? Could it effect stockprice and marketsentiment?

1 · Reply

Captaincoin1 Feb. 22 at 5:58 PM

$AKBA

1 · Reply

TheGreedyGrinch Feb. 22 at 3:44 PM

$AKBA

0 · Reply

Magic_Money Feb. 22 at 1:58 PM

$AKBA What is interesting to me as a long term long is that we are finally getting a reset with (TIW) that will move us forward capturing more market share and the majority of the board comments are negative. This is the first Q of the reset. Q1 hasn’t even reported yet. TDAPA has flaws and they really showed up for Kidney care, but Congress has a chance to help fix some of them through reform and extending the duration of TDAPA. Looking for 40-50K Medicare patients on V by the end of the year. We could double that if Fresenius jumps on board this year. Still hoping the FDA wakes up to allowing V for a subset group of NDD patients. Maybe the Vocal and Voice studies will help with that. Anyway this year must be way better than all the previous years combined.

1 · Reply

gaboriar Feb. 22 at 1:24 PM

$AKBA Welcome to ER week. If you are new money so much opportunity here. Especially if you are only looking for a 2X payout. This is actually tempting me to go get new money and BORROW $200K. Then write the calls take the premium and immediately pay down the loan to under $100K Trade idea NFA: Buy commons: $1.20 Sell $1 jan calls : .80 cents New avg .40 cents You break even at .50 ( inc holding cost and opportunity lost cost) Max payout $1 which is 100% profit . All you need is for akba to limp into January around $1

1 · Reply

gaboriar Feb. 22 at 1:15 PM

$AKBA make the argument that Daprodustat is or is NOT non- inferior to Vadadustat.

1 · Reply

NovaReincarnasada Feb. 22 at 12:32 PM

$AKBA this is what he tells his man every night. What a loss 😂

1 · Reply

Market Cap	313.13M
Revenue (ttm)	160.18M
Net Income (ttm)	-69.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	10.11
Profit Margin	-43.33%
Debt to Equity Ratio	1.15

Volume	2,541,100
Avg Vol	3,219,358
Day's Range	N/A - N/A
Shares Out	265.37M
Stochastic %K	9%
Beta	0.38
Analysts	Strong Sell
Price Target	$4.60